Mark Alan Smith is CHIEF MEDICAL OFFICER of VistaGen Therapeutics, Inc.. Currently has a direct ownership of 19,915 shares of VTGN, which is worth approximately $61,935. The most recent transaction as insider was on Jun 30, 2022, when has been sold 5,000 shares (Common Stock) at a price of $0.75 per share, resulting in proceeds of $3,750. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 19.9K
0% 3M change
0% 12M change
Total Value Held $61,935

Mark Alan Smith Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 30 2022
BUY
Grant, award, or other acquisition
$3,750 $0.75 p/Share
5,000 Added 20.07%
19,915 Common Stock
Dec 31 2021
BUY
Grant, award, or other acquisition
$4,407 $1.66 p/Share
2,655 Added 15.11%
14,915 Common Stock
Jun 30 2021
BUY
Grant, award, or other acquisition
$4,407 $1.95 p/Share
2,260 Added 15.56%
12,260 Common Stock
Dec 31 2020
BUY
Grant, award, or other acquisition
$2,250 $0.45 p/Share
5,000 Added 33.33%
10,000 Common Stock
MAS

Mark Alan Smith

CHIEF MEDICAL OFFICER
South San Francisco, CA

Track Institutional and Insider Activities on VTGN

Follow VistaGen Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VTGN shares.

Notify only if

Insider Trading

Get notified when an Vista Gen Therapeutics, Inc. insider buys or sells VTGN shares.

Notify only if

News

Receive news related to VistaGen Therapeutics, Inc.

Track Activities on VTGN